Rhodia buys Chinese chemicals firm
This article was originally published in The Rose Sheet
Executive Summary
French specialty chemicals firm announces acquisition of Feixiang Chemicals of China for $489 mil. Feixiang - one of the leading producers of fatty amines and specialty amines - will help Rhodia strengthen its position in the specialty surfactant business for personal care, firm says. After deal's closing - expected in the second half of 2010 - Rhodia will generate one-third of its net sales in Asia, and Rhodia plans to double the size of Feixiang's business in the next five years
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.